William T. Abraham Joins Cardiac Dimensions as Chief Medical Officer

Cardiac Dimensions has appointed William T. Abraham, M.D., as chief medical officer. A globally recognized expert in heart failure and device-based therapies, Dr. Abraham will help lead the company’s clinical and regulatory strategies as it advances toward U.S. regulatory approval and expands European sales of the Carillon Mitral Contour System.

“We are delighted to welcome Dr. Abraham to the Cardiac Dimensions leadership team,” Cardiac Dimensions President/CEO Rick Wypych said. “Bill’s impact on the heart failure field is unmatched. His input and influence on the Carillon therapy will help drive the success and adoption of this therapy. In addition, his experience with large-scale clinical trials and regulatory pathways will be instrumental to the completion of our pivotal U.S. landmark study—The EMPOWER Trial.”

Dr. Abraham most recently served as chief medical officer at V-Wave Ltd., where he led the U.S. pivotal trial and played a key role in advancing the company’s transcatheter interatrial shunt therapy, culminating in a significant heart failure-focused acquisition by Johnson & Johnson.

Dr. Abraham is a College of Medicine Distinguished Professor at The Ohio State University, where he directed the Division of Cardiovascular Medicine for more than 15 years, and has published over 650 peer-reviewed papers. He is internationally known for his leadership in advancing heart failure treatments, including cardiac resynchronization therapy, remote hemodynamic monitoring, and transcatheter valve repair. Dr. Abraham has also served as national or global principal investigator on more than 50 multicenter trials, including important trials within the mitral valve space.

“I’ve spent my career working to bring novel and impactful therapies to people living with heart failure,” Dr. Abraham stated. “What drew me to Cardiac Dimensions is the Carillon therapy’s unique position in the heart failure treatment paradigm. It offers a physiologically elegant approach to reducing mitral regurgitation, preserving future treatment options, and modifying the disease process itself. I’m particularly encouraged by the consistent data showing favorable atrial and ventricular remodeling, symptom improvement, and a excellent safety profile, even in patients with proportionate MR who are often excluded from other therapies.”

The Carillon Mitral Contour System has received CE Mark and is available for sale in Europe and other countries that recognize CE Mark. The Carillon Mitral Contour System is a minimally invasive device that treats heart failure patients with functional mitral regurgitation by reshaping the mitral valve apparatus through the coronary sinus. It is commercially available in Europe, as well as other countries, and is currently being studied in the U.S. pivotal EMPOWER Trial.

The EMPOWER Trial is a prospective, randomized, sham-controlled pivotal study designed to enroll up to 300 patients across U.S. and international centers. The trial aims to support U.S. Food and Drug Administration approval by demonstrating the Carillon therapy’s potential to improve symptoms, cardiac structure, and long-term outcomes in a broad heart failure population.

Cardiac Dimensions is addressing the patient population suffering from heart failure with functional mitral regurgitation. With decades of clinical experience and thousands of patients treated worldwide, the company’s Carillon device is positioned as a durable therapy designed to treat early and late-stage patients, improve symptoms and reverse disease progression.

The Carillon System is an investigational device limited by U.S. law to investigational use.